Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Aurora Cannabis Inc (ACB) vs Smith & Nephew plc (SNN) Price & Performance

Aurora Cannabis IncTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Aurora Cannabis Inc vs Smith & Nephew plc — how do they compare? Aurora Cannabis Inc trades at $3.49 (market cap $178.92M), while Smith & Nephew plc trades at $30.03 (market cap $12.50B). The key difference: Smith & Nephew plc is far larger — about 69.9× Aurora Cannabis Inc's market cap, and Smith & Nephew plc pays a 2.64% dividend while Aurora Cannabis Inc pays none. Which is the better fit depends on your goals.

ACBSNN
Market Cap
$178.92M$12.50B
Sector
HealthHealth
52-Week High
$6.23$38.70
52-Week Low
$2.58$28.73
Enterprise Value
$123.48M$15.53B
Dividend Yield
2.64%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Aurora Cannabis Inc

Aurora Cannabis (ACB) trades at $2.99, up 0.34% with a bullish technical signal despite mixed earnings. The company achieved record annual medical cannabis revenue growth of 18% YoY to $288.6 million in FY2026, but faces margin pressure from Canadian reimbursement changes. Recent Q1 2027 earnings beat expectations with $0.04 EPS versus -$0.13 estimate, though revenue declined to $67.6 million. The stock shows strong institutional support with shareholder approval of board measures and EU-GMP certification for international expansion.

ACB presents a high-risk opportunity with significant volatility. While international medical cannabis growth and operational improvements provide upside potential, persistent net losses, negative ROE/ROA, and Canadian market challenges create substantial headwinds. Analyst consensus remains cautious with only 21% buy ratings, reflecting concerns about profitability timeline and competitive pressures in the evolving cannabis sector.

Smith & Nephew plc

SNN trades at $30.11, up 1.41% in the last session. Technical indicators are bearish, with moving averages signaling a downtrend. Fundamentally, the company reported Q2 2026 revenue growth of 1.6% but cut its full-year outlook to 4% from 6% due to weakness in U.S. Orthopaedics and Advanced Wound Bioactives (MarketBeat, 2026-08-09). Recent product launches include the LYNX COBLATION Wand and CORI XT robotics platform, supporting innovation in medical technology.

The outlook is mixed: strong profitability margins and recent earnings beats offer support, but lowered guidance and bearish technicals pose near-term headwinds. Risks include execution challenges in key markets, while analyst consensus leans Hold, reflecting cautious optimism amid growth uncertainties.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Aurora Cannabis Inc

Aurora Cannabis, based in Edmonton, Canada, grows and distributes both medical and recreational cannabis under several brands, including Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. While its main market is Canada, the company has also expanded globally through medical cannabis export agreements.

Read more on ACB

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN